Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis

References

• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001. doi: 10.1038/nrdp.2018.1
   PubMed Web of Science ®Google Scholar
• Mclnnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328–2337. doi: 10.1016/S0140-6736(17)31472-1
   PubMed Web of Science ®Google Scholar
• Mclnnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immnol. 2021;21:680–686. doi: 10.1038/s41577-021-00603-1
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Rheumatoid arthritis. Inflamm Regen. 2020;40:20. doi: 10.1186/s41232-020-00133-8
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology. 2021;60(Supplement_6):vi12–20. doi: 10.1093/rheumatology/keab609
   PubMedGoogle Scholar
• Taisho Pharmaceutical Co., Ltd., Tokyo. Nanozora (ozoralizumab) 30 mg syringes for S.C. Injection Package Insert; 2022. [ Japanese; cited 2023 Jan 5]. Available from: www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400059_3999467G1023_1_01.
   Google Scholar
• Ishiwatari-Ogata C, Kyuuma M, Ogata H, et al. Ozoralizumab, a humanized anti-TNFα NANOBODY® compound, exhibits efficacy not only at the onset of arthritis in a human TNF transgenic mouse but also during secondary failure of administration of an anti-TNFα IgG. Front Immunol. 2022;13:853008 doi: 10.3389/fimmu.2022.853008
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Balsam JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–637. doi: 10.1136/ard.2009.123919
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. doi: 10.1136/ard-2022-223356
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumat. 2021;73:1108–1123. doi: 10.1002/art.41752
   PubMed Web of Science ®Google Scholar
• Zampeli E, Vlachoyiannopoulos PG, Tzioufas AG. Treatment of rheumatoid arthritis: unraveling the conundrum. J Autoimmun. 2015;65:1–18. doi: 10.1016/j.jaut.2015.10.003
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–448. doi: 10.1038/363446a0
   PubMed Web of Science ®Google Scholar
• Arbabi-Ghahroudi M Camelid single-domain antibodies: historical perspective and future outlook. Front Immunol. 2017;8:1589. doi: 10.3389/fimmu.2017.01589
   Google Scholar
• Muyldermans S, Baral TN, Retamozzo VC, et al. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol. 2009;128:178–183. doi: 10.1016/j.vetimm.2008.10.299
   PubMed Web of Science ®Google Scholar
• Steeland S, Vandenbroucke RE, Libert C, et al. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016;21:1076–1113. doi: 10.1016/j.drudis.2016.04.003
   PubMed Web of Science ®Google Scholar
• Crowe JS, Roberts KJ, Carlton TM, et al. Preclinical development of a novel, orally-administered anti-tumour necrosis factor domain antibody for the treatment of inflammatory bowel disease. Sci Rep. 2018;8(1):4941. doi: 10.1038/s41598-018-23277-7
   PubMedGoogle Scholar
• Nurbhai S, Roberts KJ, Carlton TM, et al. Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients. Sci Rep. 2019;9(1):14042. doi: 10.1038/s41598-019-50545-x
   PubMed Web of Science ®Google Scholar
• Duggan S. Caplacizumab: first global approval. Drugs. 2018;78(15):1639–1642. doi: 10.1007/s40265-018-0989-0
   PubMed Web of Science ®Google Scholar
• Besnerais M, Veyradier A, Benhamou Y, et al. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opin Biol Ther. 2019;19:1127–1134. doi: 10.1080/14712598.2019.1650908
   PubMed Web of Science ®Google Scholar
• Taisho Pharmaceutical Co., Ltd. The pharmaceutical common technical document for Nanozora (ozoralizumab) 30 mg Syringes for S.C. Injection; 2022. [ Japanese; cited 2023 Jan 5]. Available from: www.pmda.go.jp/drugs/2022/P20220824002/index.html.
   Google Scholar
• Hoefman S, Ottevaere I, Baumeister J, et al. Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended nanobodies®. Antibodies. 2015;4(3):141–156. doi: 10.3390/antib4030141
   Web of Science ®Google Scholar
• Zorzi A, Linciano S, Angelini A. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Med Chem Comm. 2019;10:1068–1081. doi: 10.1039/C9MD00018F
   Google Scholar
• Takeuchi T, Chino Y, Kawanishi M, et al. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis Res Ther. 2023;25(1). doi: 10.1186/s13075-023-03036-4
   Web of Science ®Google Scholar
• Coppieters K, Dreier T, Silence K, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 2006;54:1856–1866 doi:10.1002/art.21827.
   PubMed Web of Science ®Google Scholar
• Oyama S, Ebina K, Etani Y, et al. A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. Sci Rep. 2022;12(1):18102. doi: 10.1038/s41598-022-23152-6
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000;27:841–850.
   PubMed Web of Science ®Google Scholar
• AbbVie GK Adalimumab (Humira) package insert; 2022. [ Japanese; cited 2022 Dec 13] Available from: https://a-connect.abbvie.co.jp/-/media/assets/pdf/products/humira/humira_tmpDocuments.pdf.
   Google Scholar
• Ling J, Lyn S, Xu Z, et al. Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. J Clin Pharmacol. 2010;50:792–802. doi: 10.1177/0091270009355162
   PubMed Web of Science ®Google Scholar
• Kawai S, Sekino H, Yamashita N, et al. The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol. 2006;46:418–423. doi: 10.1177/0091270006286435
   PubMed Web of Science ®Google Scholar
• Wade JR, Parker G, Kosutic G, et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn’s disease. J Clin Pharmacol. 2015;55:866–874. doi: 10.1002/jcph.491
   PubMed Web of Science ®Google Scholar
• UCB Japan Co. Ltd. Certolizumab pegol (Cimzia) package insert; 2022. [ Japanese; cited 2022 Dec 13]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/820110_3999437G1022_1_17.
   Google Scholar
• Takeuchi T, Kawanishi M, Nakanishi M, et al. Phase II/III results of a trial of anti-tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis. Arthritis & Rheumat. 2022;74:1776–1785 doi:10.1002/art.42273.
   PubMedGoogle Scholar
• Tanaka Y, Kawanishi M, Nakanishi M, et al. Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 52-week result of a Phase II/III study (OHZORA trial). Mod Rheumatol. 2022;32(2):263–272. doi: https://doi.org/10.1093/mr/roac119
   PubMedGoogle Scholar
• Tanaka Y, Kawanishi M, Nakanishi M, et al. Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: a 52-week result of phase III, randomised, open-label trial (NATSUZORA trial). Mod Rheumatol. 2022. doi: 10.1093/mr/roac126.
   Web of Science ®Google Scholar
• Taylor PC, Ancuta C, Nagy O, et al. Treatment satisfaction, patient preferences, and the impact of suboptimal disease control in a large international rheumatoid arthritis cohort: SENSE study. Patient Prefer Adherence. 2021;15:359–373. doi: 10.2147/PPA.S289692
   PubMed Web of Science ®Google Scholar
• Rahman MU, Buchanan J, Doyle MK, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis. 2011;70:1631–1640. doi: 10.1136/ard.2010.146043
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Landewé R. Should radiographic progression still be used as outcome in RA? Clin Immunol. 2018;186:79–81. doi: 10.1016/j.clim.2017.07.022
   PubMed Web of Science ®Google Scholar
• Matsubara T, Inoue H, Nakajima T, et al. Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomized placebo-controlled phase IV study. RMD Open. 2018;4:e000813. doi: 10.1136/rmdopen-2018-000813
   PubMed Web of Science ®Google Scholar